The patient was diagnosed with invasive ductal
carcinoma of the breast.
患者被诊断为乳腺浸润性导管癌。
Early detection of squamous cell
carcinoma can significantly improve treatment outcomes.
早期发现鳞状细胞癌能显著提高治疗效果。
The biopsy results confirmed the presence of renal cell
carcinoma in the patient's kidney.
活检结果证实患者肾脏存在肾细胞癌。
He underwent surgery to remove a malignant melanoma from his shoulder.
他接受了手术，切除了肩膀上的恶性黑素瘤。
The oncologist recommended chemotherapy for treating her advanced ovarian
carcinoma.
肿瘤医生建议采用化疗来治疗她的晚期卵巢癌。
The study aimed to investigate the genetic factors associated with the development of colorectal
carcinoma.
该研究旨在探讨与结直肠癌发生相关的遗传因素。
Non-small cell lung
carcinoma is the most common type of lung cancer, accounting for about 85% of cases.
非小细胞肺癌是最常见的肺癌类型，约占病例的85%。
Regular self-examination can help detect early signs of basal cell
carcinoma, a common form of skin cancer.
定期自我检查有助于发现基底细胞癌（一种常见皮肤癌）的早期迹象。
The patient's thyroid
carcinoma was detected incidentally during a routine ultrasound scan.
患者在例行超声检查中偶然发现了甲状腺癌。
Immunotherapy has shown promising results in treating certain types of advanced-stage hepatocellular
carcinoma.
免疫疗法在治疗某些类型的晚期肝细胞癌方面显示出有前景的结果。
The Chinese biotech and its US partner Coherus BioSciences Inc jointly announced on Oct 27 that the US FDA approved Loqtorzi (toripalimab-tpzi) in combination with other drugs for the first-line treatment of adults with metastatic or recurrent locally advanced metastatic nasopharyngeal carcinoma (NPC), and as monotherapy for the treatment of adults with recurrent, or metastatic NPC with disease progression on or after platinum-containing chemotherapy.
10月27日，中国生物技术公司及其美国合作伙伴Cohereus BioSciences Inc联合宣布，美国FDA批准Loqtorzi（托帕利单抗-tpzi）与其他药物联合用于成人转移性或复发性局部晚期转移性鼻咽癌（NPC）的一线治疗，或在含铂化疗时或之后具有疾病进展的转移性NPC。
Similarly, another product that debuted at the second CIIE for the treatment of unresectable hepatocellular carcinoma, has entered into a local partnership in Chengdu, capital of Sichuan province.
另一款在第二届进博会首发的、用于治疗不可切除肝细胞癌的药品，已与四川成都的本地伙伴达成合作。
A total of six new drugs and indications, including those for patients suffering from melanoma, ankylosing spondylitis (a rheumatic immune disease), and non-small cell carcinoma, were approved in China last year.
去年，中国批准了六种新药和适应症，包括针对黑色素瘤、强直性脊柱炎（一种风湿免疫疾病）和非小细胞肺癌的药物。
The exhibits include the world's first immunotherapy for the first-line treatment of patients with unresectable hepatocellular carcinoma.
这些展品包括全球首款用于一线治疗不可切除肝细胞癌患者的免疫疗法。
Junshi Biosciences, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced on Thursday the US Food and Drug Administration has recently granted Breakthrough Therapy designation to its cancer drug Toripalimab for the treatment of nasopharyngeal carcinoma, or cancer that occurs in the nasopharynx.
Li Ning, chief executive officer of Junshi Biosciences, said the company found great unmet medical needs exist in other countries where patients are endangered by this deadly disease, although it prioritizes cancer types with high prevalence in China such as nasopharyngeal carcinoma, lung and liver cancer.
This research group started in 2006 to focus mainly on diseases prevalent in China and Asia, such as liver cancer, gastric cancer, and nasopharyngeal carcinoma, a type of head and neck cancer.
Votrient is for a form of kidney cancer called advanced renal cell carcinoma and the medicine Jakavi is for myelofibrosis, a bone marrow condition.
In April, China's National Medical Products Administration approved the company's anti-PD-1 antibody tislelizumab as a treatment for patients with locally advanced or metastatic urothelial carcinoma, the most common type of bladder cancer, following the therapy's initial approval in classic Hodgkin's lymphoma in December 2019.
在4月，中国国家药品监督管理局批准了该公司的抗PD-1抗体tislelizumab用于治疗局部晚期或转移性尿路上皮癌（最常见的膀胱癌）的患者，此前该疗法于2019年12月首次被批准用于经典霍奇金淋巴瘤。
Tislelizumab received approval from the China National Medical Products Administration last April as a treatment for patients with locally advanced or metastatic urothelial carcinoma, the most common type of bladder cancer, following the therapy's initial approval in classical Hodgkin's lymphoma by the NMPA in December 2019.
They are first-line treatment of patients with advanced squamous non-small cell lung cancer in combination with chemotherapy, first-line treatment of patients with advanced non-squamous NSCLC in combination with chemotherapy, and previously treated unresectable hepatocellular carcinoma.
China's biotechnology company BeiGene Ltd announced on Saturday that its anti-PD-1 antibody tislelizumab, an immunotherapy, had received approval from the China National Medical Products Administration as a treatment for patients with locally advanced or metastatic urothelial carcinoma (UC), the most common type of bladder cancer, following the therapy's initial approval in classical Hodgkin's lymphoma by the NMPA in December.
The newly approved indication, for patients suffering from locally advanced or metastatic urothelial carcinoma with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy, is the first in a solid tumor indication.
未经许可，严禁转发。QQ交流群：688169419